- Research Assistant Professor, ASU Neurodegenerative Disease Research Center (NDRC) (2019 - present)
- Post Doctoral, ASU NDRC (2014-2019) ?
- PhD, Cornell University, Ithaca NY (Aug. 2008- Aug 2014)???
- BA, California State University, Long Beach (May 2002- May 2007)
As a neuroscientist, I have been mainly interested in deciphering the early molecular events that contribute to the pathogenesis of various neurodevelopmental and neurodegenerative diseases. In particular, I am interested in identifying new therapeutic targets for discovery of drugs that can ameliorate disease progression. Our lab uses a combination of post mortem human brain tissue in addition to various lines of animal models of Down Syndrome (DS) and Alzheimer's Disease (AD) to test our hypotheses. I strongly believe that in order to progress outcomes within research, collaborations are key. Sharing knowledge through publications, mentorship, teaching and public seminars have been key to furthering my scientific career. My ultimate goal is to make a large impact by both progressing science and consecutively helping those who suffer from insidious diseases.
Dr. Ramon Velazquez is an Assistant Research Professor at the Neurodegenerative Disease Research Center at the Biodesign Institute - Arizona State University (ASU). His research interests include identifying novel therapeutic targets for neurodegenerative disorders such as Alzheimer?s disease (AD) and Down Syndrome (DS). In particular, he focuses on early molecular events that trigger the progression of these diseases. He is also interested in drug discovery and dietary supplementation of B-like vitamins as a way to prevent disease progression. Dr. Velazquez received his doctoral degree at Cornell University and worked in the laboratory of Dr. Barbara Strupp in collaboration with training in the laboratory of Dr. Elliot Mufson at Rush University. Dr. Velazquez was funded by the National Science Foundation (NSF) Pre-Doctoral fellowship as a graduate student. He completed his Post-Doctoral training in molecular biology and neuroscience at ASU, where he was independently funded by the Alzheimer?s Association to investigate a novel therapeutic drug therapy (Pim1-inhibitor) leveraging the use of nanoparticle encapsulation to halt the progression of AD-pathology. Additionally, he was funded through a NSF Post-Doctoral fellowship to elucidate the exact molecular mechanisms linked to Choline?s cognitive and neural benefits. Dr. Velazquez?s ultimate goal is to progress science while consecutively helping those who suffer from insidious neurodegenerative diseases.